These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 22474603)

  • 21. Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome/X-linked mental retardation.
    Jentarra GM; Olfers SL; Rice SG; Srivastava N; Homanics GE; Blue M; Naidu S; Narayanan V
    BMC Neurosci; 2010 Feb; 11():19. PubMed ID: 20163734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of differentiation (ID1, ID2, ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett syndrome.
    Peddada S; Yasui DH; LaSalle JM
    Hum Mol Genet; 2006 Jun; 15(12):2003-14. PubMed ID: 16682435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes.
    Yasui DH; Peddada S; Bieda MC; Vallero RO; Hogart A; Nagarajan RP; Thatcher KN; Farnham PJ; Lasalle JM
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19416-21. PubMed ID: 18042715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
    Gadalla KK; Bailey ME; Cobb SR
    Biochem J; 2011 Oct; 439(1):1-14. PubMed ID: 21916843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MeCP2 Dysfunction in Rett Syndrome and Neuropsychiatric Disorders.
    Chin EWM; Goh ELK
    Methods Mol Biol; 2019; 2011():573-591. PubMed ID: 31273722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mecp2-null mice provide new neuronal targets for Rett syndrome.
    Urdinguio RG; Lopez-Serra L; Lopez-Nieva P; Alaminos M; Diaz-Uriarte R; Fernandez AF; Esteller M
    PLoS One; 2008; 3(11):e3669. PubMed ID: 18989361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Karyopherin α 3 and karyopherin α 4 proteins mediate the nuclear import of methyl-CpG binding protein 2.
    Baker SA; Lombardi LM; Zoghbi HY
    J Biol Chem; 2015 Sep; 290(37):22485-93. PubMed ID: 26245896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome.
    Brown K; Selfridge J; Lagger S; Connelly J; De Sousa D; Kerr A; Webb S; Guy J; Merusi C; Koerner MV; Bird A
    Hum Mol Genet; 2016 Feb; 25(3):558-70. PubMed ID: 26647311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First report of an unusual novel double mutation affecting the transcription repression domain of MeCP2 and causing a severe phenotype of Rett syndrome: Molecular analyses and computational investigation.
    Ghorbel R; Ghorbel R; Rouissi A; Fendri-Kriaa N; Ben Salah G; Belguith N; Ammar-Keskes L; Gouider-Khouja N; Fakhfakh F
    Biochem Biophys Res Commun; 2018 Feb; 497(1):93-101. PubMed ID: 29421650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients.
    Lilja T; Wallenborg K; Björkman K; Albåge M; Eriksson M; Lagercrantz H; Rohdin M; Hermanson O
    Epigenetics; 2013 Mar; 8(3):246-51. PubMed ID: 23348913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rett syndrome and MeCP2.
    Liyanage VR; Rastegar M
    Neuromolecular Med; 2014 Jun; 16(2):231-64. PubMed ID: 24615633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MeCP2 Rett mutations affect large scale chromatin organization.
    Agarwal N; Becker A; Jost KL; Haase S; Thakur BK; Brero A; Hardt T; Kudo S; Leonhardt H; Cardoso MC
    Hum Mol Genet; 2011 Nov; 20(21):4187-95. PubMed ID: 21831886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rett syndrome: disruption of epigenetic control of postnatal neurological functions.
    Pohodich AE; Zoghbi HY
    Hum Mol Genet; 2015 Oct; 24(R1):R10-6. PubMed ID: 26060191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype.
    Hoffbuhr KC; Moses LM; Jerdonek MA; Naidu S; Hoffman EP
    Ment Retard Dev Disabil Res Rev; 2002; 8(2):99-105. PubMed ID: 12112735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA methylation in the gene body influences MeCP2-mediated gene repression.
    Kinde B; Wu DY; Greenberg ME; Gabel HW
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15114-15119. PubMed ID: 27965390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research progress of Rett syndrome causing gene MECP2--the structure, function and modulation of MECP2].
    Zhang JJ; Bao XH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Dec; 41(6):712-5. PubMed ID: 20019788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome.
    Buschdorf JP; Strätling WH
    J Mol Med (Berl); 2004 Feb; 82(2):135-43. PubMed ID: 14618241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MECP2 mutations in Rett syndrome adversely affect lymphocyte growth, but do not affect imprinted gene expression in blood or brain.
    Balmer D; Arredondo J; Samaco RC; LaSalle JM
    Hum Genet; 2002 Jun; 110(6):545-52. PubMed ID: 12107440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Novel function of MeCP2 in the pathophysiology of Rett syndrome: Regulation of mTOR signaling mediated by MeCP2-dependent microRNA processing].
    Tsujimura K; Nakashima K
    Seikagaku; 2017 Feb; 89(1):51-61. PubMed ID: 29624958
    [No Abstract]   [Full Text] [Related]  

  • 40. Spectrum of MECP2 mutations in New Zealand Rett syndrome patients.
    Raizis AM; Saleem M; MacKay R; George PM
    N Z Med J; 2009 Jun; 122(1296):21-8. PubMed ID: 19652677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.